Amber Bio

Biotech & Life Sciences · San Francisco, United States · Founded 2021

A biotechnology company developing a first-of-its-kind RNA writing platform using multi-kilobase edits to reach previously undruggable patient populations, pioneering new gene editing modalities for… MoreLess

Amber Bio is a biotechnology company that has developed a platform for RNA editing. This platform allows for the editing of multi-kilobase RNA strands, which can be used to correct genetic mutations that cause diseases.

The company's technology is based on a deep understanding of RNA biology and machine learning. Amber Bio's platform has the potential to treat a wide range of diseases, including genetic disorders, cancer, and infectious diseases.

Amber Bio was founded in 2023 by a team of experienced scientists and entrepreneurs. The company has raised $26 million in seed financing from Playground Global and Andreessen Horowitz.

Keywords: RNA editing, gene therapy, biotechnology, genetic disorders, cancer, infectious diseases, machine learning, drug development, therapeutics, platform

Valuation $100–500M

Headcount <100

Total funding $10–50M

Unlock exact values

Company overview

Amber Bio company information

The essential company record, classifications and operating signals in one place.

Status: Operational
Founded: 2021
Headquarters: San Francisco, United States
Employees: 24
Open positions: None listed
Dealroom signal: 80.4

Website ↗LinkedIn ↗

client focusb2bsub industryBioTechnologybusiness modelManufacturingindustryHealthsectorBiotechnologysectorSpinoutsectorBiotech and PharmasectorDT and LSsectorscience-based

Valuation & funding

Amber Bio funding history

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SEED✓Equity / VC	Aug 2023	$26M	$104M	Hummingbird Ventures · Playground Global · Eli Lilly · Pillar VC	↗
SPINOUT✓Other financing	Dec 2021	$0	—	University of California, Berkeley	—

Showing 2 recorded eventsUnlock the complete deal history →

Financials

Workforce over time

Available workforce history. Financial fields without reported data are omitted.

Year	Employees
2026	24
2025	21
2024	18
2023	9

Company filings, research estimates and Dealroom dataOpen the full financial model →

Growth signals

Amber Bio website traffic

Latest recorded traffic for Amber Bio is 5.6K monthly website visits, up 124% over the last three months. Amber Bio's team grew 14.3% over the past year.

Latest monthly visits5.6K 3-month web change+124% 1-year team growth+14.3%

Monthly website visits36 observations · Aug 2023–Jul 2026

Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Amber Bio compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
PRPrecirixCamelid-derived radiopharmaceuticals for targeted cancer therapy	Jette, Belgium	Operational	9	$130M	$352M
SPStrike PharmaDevelops a novel next generation Antibody-Drug Conjugate (ADC) technology, the ADAC technology	Uppsala kommun, Sweden	Operational
PTPROSION TherapeuticsPROSION Therapeutics is a drug development company with a proprietary platform that addresses highly unmet medical needs by unlocking undruggables	Cologne, Germany	Operational
OLOlgramInnovations from the sea to tackle antibiotic resistance \| Olgram	Paris, France	Operational
ATAsgard TherapeuticsSpin-off company from Lund University focusing on developing cancer immunotherapies based on cell fate reprogramming	Lund Municipality, Sweden	Operational
CTCARsgen TherapeuticsA leading immunotherapy company focused on the development of new chimeric antigen receptor	Xuhui District, China	Operational
ABAnnexon BiosciencesBiotech company, discovering and developing novel therapeutics for neurodegenerative and autoimmune disorders	San Francisco, United States	Operational
ELElasmogenNext generation therapeutic biologics company discovering and developing drugs	Aberdeen, United Kingdom	Operational

Showing 8 of the closest matchesCompare every metric →

Talent graph

Amber Bio's talent

Book a demo to see the people

Team profiled 5 named & role-tagged

Founders /100 quality score

Key operators 2 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

8 investors on Amber Bio's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Seed 6 investors entered at this stage

Andreessen Horowitz

Hummingbird Ventures

Playground Global

Eli Lilly

Pillar VC

Retinal Degeneration Fund

Other known 2 additional known investors

University of California, Berkeley

Benjamin Kim

Global footprint

Where Amber Bio has talent and traffic

Workforce by country

2 countries with
team presence

🇺🇸 United States95.5%

🇳🇬 Nigeria4.5%

2 countries shown

In the news

Latest news about Amber Bio

Recent press, funding announcements, and product moves mentioning Amber Bio — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Amber Bio

An AI-synthesized read of the highest-engagement posts about Amber Bio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Amber Bio’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.